EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 35 / No 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1189-1193 References
Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1189 - 1193
Section Les anticorps à l’aune des analyses médico-économiques
DOI https://doi.org/10.1051/medsci/2019212
Published online 06 January 2020
  1. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012 ; 380: 1819–1828. [CrossRef] [PubMed] [Google Scholar]
  2. Editorial. Alemtuzumab for multiple sclerosis. Lancet 2012; 380: 1792. [Google Scholar]
  3. Montgomery SM, Kusel J, Nicholas R, et al. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. J Med Econ. 2017 ; 20: 962–973. [CrossRef] [PubMed] [Google Scholar]
  4. Piena MA, Heisen M, Wormhoudt LW, et al. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. J Med Econ. 2018 ; 21: 968–976. [CrossRef] [PubMed] [Google Scholar]
  5. Stanisic S, Bertolotto A, Berto P, et al. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. GRHTA. 2019 ; 21: S338. [Google Scholar]
  6. Marmor MF, Martin LJ, Tharpe S, et al. Osmotically induced retinal detachment in the rabbit and primate. Electron miscoscopy of the pigment epithelium. Invest Ophthalmol Vis Sci 1980 ; 19: 1016–1029. [PubMed] [Google Scholar]
  7. de Oliveira Dias JR, Badaró E, Novais EA, et al. Preclinical investigations of intravitreal ziv-aflibercept. Ophthalmic Surg Lasers Imaging Retina 2014 ; 45: 577–584. [CrossRef] [PubMed] [Google Scholar]
  8. Mansour AM, Ashraf M, Charbaji A, et al. Two-year outcomes of intravitreal ziv-aflibercept. Br J Ophthalmol 2018 ; 102: 1387–1390. [CrossRef] [PubMed] [Google Scholar]
  9. Mansour AM, Chhablani J, Antonios RS, et al. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration. Br J Ophthalmol 2016 ; 100: 1629–1633. [CrossRef] [PubMed] [Google Scholar]
  10. Chan EW, Eldeeb M, Govindhari V, et al. Treatment outcomes of ziv-aflibercept for treatment-naïve polypoidal choroidal vasculopathy. Acta Ophthalmol 2018 ; 96: e258–e259. [CrossRef] [PubMed] [Google Scholar]
  11. Chhablani J, Dedhia CJ, Peguda HK, et al. Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina 2017 ; 37: 1859–1865. [CrossRef] [PubMed] [Google Scholar]
  12. Mansour AM, Al-Ghadban SI, Yunis MH, et al. Ziv-aflibercept in macular disease. Br J Ophthalmol 2015 ; 99: 1055–1059. [CrossRef] [PubMed] [Google Scholar]
  13. Andrade GC, Dias JR, Maia A, et al. Intravitreal injections of ziv-aflibercept for diabetic macular edema: a pilot study. Retina 2016 ; 36: 1640–1645. [CrossRef] [PubMed] [Google Scholar]
  14. Singh SR, Dogra A, Stewart M. Intravitreal ziv-aflibercept: clinical effects and economic impact. Asia Pac J Ophthalmol (Phila) 2017 ; 6: 561–568. [Google Scholar]
  15. Magdelaine-Beuzelin C, Pinault C, Paintaud G, et al. Therapeutic antibodies in ophthalmology: old is new again. MAbs 2010 ; 2: 176–180. [CrossRef] [PubMed] [Google Scholar]
  16. CATT Research Group, Martin DF, Maguire MG, Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011 ; 364: 1897–1908. [Google Scholar]
  17. Chakravarthy U, Harding SP, Rogers CA, et al. IVAN 2-years Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013 ; 2012: 382 1258–1267. [Google Scholar]
  18. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013 ; 97: 266–271. [CrossRef] [PubMed] [Google Scholar]
  19. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL non-inferiority randomized trial. Ophtalmol 2013 ; 120: 2300–2309. [CrossRef] [Google Scholar]
  20. Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015 ; 122: 146–152. [Google Scholar]
  21. Schauwvlieghe AM, Dijkman G, Hooymans JM, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study. PLoS One 2016 ; 11: e0153052. [CrossRef] [Google Scholar]
  22. Chast F.. Coût du traitement de la DMLA: au cœur de la polémique. Rev Prat (médecine générale) 2017 ; 975: 121–122. [Google Scholar]
  23. Rapport annuel de la cour des comptes. Paris, 2018: p. 268. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.